These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Gas chromatography-mass spectrometry profiling of steroids in urine of patients with acute intermittent porphyria. Casals G; Marcos J; Pozo ÓJ; Aguilera P; Herrero C; To-Figueras J Clin Biochem; 2013 Jun; 46(9):819-24. PubMed ID: 23499585 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of the tryptophan metabolome in urine of patients with acute intermittent porphyria. Gomez-Gomez A; Marcos J; Aguilera P; To-Figueras J; Pozo OJ J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Aug; 1060():347-354. PubMed ID: 28666226 [TBL] [Abstract][Full Text] [Related]
9. Adrenal hormonal imbalance in acute intermittent porphyria patients: results of a case control study. Pozo OJ; Marcos J; Fabregat A; Ventura R; Casals G; Aguilera P; Segura J; To-Figueras J Orphanet J Rare Dis; 2014 Apr; 9():54. PubMed ID: 24735931 [TBL] [Abstract][Full Text] [Related]
10. Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion. Floderus Y; Sardh E; Möller C; Andersson C; Rejkjaer L; Andersson DE; Harper P Clin Chem; 2006 Apr; 52(4):701-7. PubMed ID: 16497943 [TBL] [Abstract][Full Text] [Related]
11. Effects of volatile anaesthetics on heme metabolism in a murine genetic model of Acute Intermittent Porphyria. A comparative study with other porphyrinogenic drugs. Ruspini SF; Zuccoli JR; Lavandera JV; Martínez MDC; Oliveri LM; Gerez EN; Batlle AMDC; Buzaleh AM Biochim Biophys Acta Gen Subj; 2018 Jun; 1862(6):1296-1305. PubMed ID: 29476795 [TBL] [Abstract][Full Text] [Related]
12. Mass spectrometric characterisation of a condensation product between porphobilinogen and indolyl-3-acryloylglycine in urine of patients with acute intermittent porphyria. Marcos J; Ibañez M; Ventura R; Segura J; To-Figueras J; Pozo OJ J Mass Spectrom; 2015 Jul; 50(7):929-37. PubMed ID: 26349648 [TBL] [Abstract][Full Text] [Related]
13. Acute intermittent porphyria: psychosis as the only clinical manifestation. Ellencweig N; Schoenfeld N; Zemishlany Z Isr J Psychiatry Relat Sci; 2006; 43(1):52-6. PubMed ID: 16910386 [TBL] [Abstract][Full Text] [Related]
14. Correlation between biochemical findings, structural and enzymatic abnormalities in mutated HMBS identified in six Israeli families with acute intermittent porphyria. Ulbrichova D; Schneider-Yin X; Mamet R; Saudek V; Martasek P; Minder EI; Schoenfeld N Blood Cells Mol Dis; 2009; 42(2):167-73. PubMed ID: 19138865 [TBL] [Abstract][Full Text] [Related]
15. Vitamin D-binding protein as a biomarker of active disease in acute intermittent porphyria. Serrano-Mendioroz I; Sampedro A; Mora MI; Mauleón I; Segura V; Enríquez de Salamanca R; Harper P; Sardh E; Corrales FJ; Fontanellas A J Proteomics; 2015 Sep; 127(Pt B):377-85. PubMed ID: 25979770 [TBL] [Abstract][Full Text] [Related]
16. Best practice guidelines on clinical management of acute attacks of porphyria and their complications. Stein P; Badminton M; Barth J; Rees D; Stewart MF; Ann Clin Biochem; 2013 May; 50(Pt 3):217-23. PubMed ID: 23605132 [TBL] [Abstract][Full Text] [Related]
17. Estimation and application of biological variation of urinary delta-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with acute intermittent porphyria. Aarsand AK; Petersen PH; Sandberg S Clin Chem; 2006 Apr; 52(4):650-6. PubMed ID: 16595824 [TBL] [Abstract][Full Text] [Related]
18. Challenges in the successful management of a case of acute intermittent porphyria in India. Patell R; Dosi R; Joshi H; Shah P; Tripathi R Trop Doct; 2016 Jul; 46(3):150-3. PubMed ID: 26472549 [TBL] [Abstract][Full Text] [Related]